Holen Sie sich die Stockscreener-App
136.12
0.38%
0.545
Schlusskurs vom Vortag:
$135.57
Offen:
$135.99
24-Stunden-Volumen:
132.84K
Relative Volume:
0.13
Marktkapitalisierung:
$13.57B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
46.14
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
-3.21%
1M Leistung:
-12.22%
6M Leistung:
+1.93%
1J Leistung:
-1.89%
1-Tages-Spanne:
$135.02
$137.07
1-Wochen-Bereich:
$134.03
$142.16
52-Wochen-Spanne:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
136.12 | 13.52B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
126.59 | 55.90B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.32 | 51.72B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.925 | 44.71B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.05 | 37.30B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
50.70 | 20.48B | 0 | -5.87M | -767.30K | -0.45 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences (NBIX) Valuation Check After KINECT DCP Phase 3 Trial Failure - Sahm
Is Neurocrine Biosciences (NBIX) Pricing Reflect Long Term Cash Flow Potential After Recent Weakness - simplywall.st
How Neurocrine Biosciences Inc. stock benefits from tech adoptionInsider Selling & Weekly Watchlist for Hot Stocks - ulpravda.ru
Why Neurocrine Biosciences Inc. stock could be next big winnerInsider Buying & Safe Swing Trade Setups - ulpravda.ru
Entry Recap: How Neurocrine Biosciences Inc stock benefits from tech adoptionMarket Growth Summary & Long-Term Capital Growth Strategies - moha.gov.vn
NBIX Analyst Downgrade by Morgan Stanley with Raised Price Targe - GuruFocus
Neurocrine Bio. stock rating downgraded by Morgan Stanley on competition - Investing.com Canada
How Neurocrine Biosciences Inc. stock performs in weak economyStock Liquidity Analysis & Affordable Growth Trading - ulpravda.ru
How Neurocrine Biosciences Inc. (NB3) stock reacts to monetary easingTechnical Analysis Insights & Crush the Market with Breakout Winners - ulpravda.ru
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX) and Moderna (MRNA) - The Globe and Mail
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
Neuroscience drugmaker CEO to speak at J.P. Morgan healthcare event - Stock Titan
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownHere's Why - MarketBeat
UBS lowers Neurocrine Bio. stock price target on competitive concerns By Investing.com - Investing.com Canada
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Exploring a 27.81% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
In Case You Missed It: Trial Updates, FDA Approvals & Rejections - Citeline News & Insights
Allspring Global Investments Holdings LLC Has $52.39 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
(NBIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VIRGINIA RETIREMENT SYSTEMS ET Al Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
13,364 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Pacer Advisors Inc. - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Downgraded by Zacks Research to "Hold" - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Stock Position Lessened by Simplify Asset Management Inc. - MarketBeat
Neurocrine Biosciences executive sells shares totaling $258,263 - MSN
Neurocrine Biosciences director Sherwin sells $1.6m in stock - MSN
Cwm LLC Has $11.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Burney Co. Has $4.05 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Neurocrine Biosciences director sells shares worth $269,167 - MSN
Neurocrine Biosciences Earnings Notes - Trefis
Swedbank AB Has $76.83 Million Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Stock News: Brighton Jones Raises Stake to $1.43M - Eudaimonia and Co
Brighton Jones LLC Has $1.43 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
AbbVie, Neurocrine End One Orilissa Patent Case Against Hetero - Bloomberg Law News
Voya Investment Management LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What's Going On With Neurocrine Biosciences Stock Tuesday?Neurocrine Biosciences (NASDAQ:NBIX) - Benzinga
Neurocrine’s valbenazine misses Phase III goals in DCP - The Pharma Letter
Neurocrine Biosciences (NBIX): Assessing Valuation After New Phase 2 Bipolar I Mania Trial Launch - Sahm
Neurocrine : Phase 3 Study Of Valbenazine In Dyskinetic Cerebral Palsy Fails To Meet Main Goal - Nasdaq
Neurocrine's Ingrezza fails in phase 3 trial for dyskinetic cerebral palsy (NBIX:NASDAQ) - Seeking Alpha
Neurocrine's movement disorder treatment fails late-stage trial - marketscreener.com
Neurocrine's Phase 3 Trial of Valbenazine in Dyskinetic Cerebral Palsy Fails to Meet Primary, Key Secondary Endpoints - marketscreener.com
Neurocrine’s phase 3 trial for cerebral palsy drug fails to meet endpoints - Investing.com
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy - PR Newswire
Assenagon Asset Management S.A. Sells 13,280 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine’s Growth Story Runs Through INGREZZA And The Pipeline - Finimize
HC Wainwright & Co. maintains Neurocrine Biosciences (NBIX) buy recommendation - MSN
What hedge fund activity signals for Neurocrine Biosciences Inc. stock2025 Valuation Update & Weekly Sector Rotation Insights - Bölüm Sonu Canavarı
How Neurocrine Biosciences Inc. stock valuations compare to rivals2025 Volatility Report & Fast Gaining Stock Reports - Улправда
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
0.18%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):